Past two years Past Year Past 30 Days
Abstract Views 409 94 1
Full Text Views 9 7 0
PDF Downloads 7 7 0
 
 
 
 
 
 
 
 
 
 
 

Anti-leishmanial IgE antibodies: a marker of active disease in visceral leishmaniasis.

A M AttaDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by A M Atta in
Current site
Google Scholar
PubMed
Close
,
D'OliveiraDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by D'Oliveira in
Current site
Google Scholar
PubMed
Close
,
J CorreaDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by J Correa in
Current site
Google Scholar
PubMed
Close
,
M L AttaDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by M L Atta in
Current site
Google Scholar
PubMed
Close
,
R P AlmeidaDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by R P Almeida in
Current site
Google Scholar
PubMed
Close
, and
E M CarvalhoDepartamento de Análises Clinicas e Toxicológicas, Faculdade de Farmácia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.

Search for other papers by E M Carvalho in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

Visceral leishmaniasis (VL) is characterized by a depression of the T helper cell type 1 immune response. Although mRNA expression for interleukin-4 (IL-4) is observed, evidence of the role of this cytokine in the pathogenesis of VL has been lacking. Since IL-4 is involved in IgE synthesis, we measured the total IgE and Leishmania antigen-specific IgE antibody levels in sera from patients with VL. Specific IgE antibodies detected by an ELISA technique after absorbing the sera with purified sheep IgG anti-human IgG were found in all 23 patients with VL and were not detected in subjects with subclinical Leishmania chagasi infection (n = 10), Chagas' disease (n = 10), atopic patients (n = 10), and healthy controls (n = 10). Levels of Leishmania-specific IgE (optical density values) before and after treatment were 0.100 +/- 0.03 (mean +/- SD) and 0.028 +/- 0.002, respectively (P < 0.05). These results indicate that a specific IgE response is useful in the diagnosis of active disease and to evaluate response to treatment.

Save